...Iris Amitay-Laish; Elena Didkovsky; Batya Davidovici; Rivka Friedland; Dan Ben Amitai; Hagai Landov; Shoshana Greenberger; Ayelet Ollech; Hadas Prag Naveh; Emmilia Hodak; Aviv Barzilai Background: Mycosis fungoides (MF) in solid-organ transplant recipients (SOTRs) is rare, with limited data...

... years (min: 1, max: 12 years), 58.1% of death causes were classified as indirect (infection), 12.9% directly related (blastic transformation), 22.5% unrelated, and 6.5% of unknown cause. 51.6% of mycosis fungoides (MF) patients who died had early-stage disease (1A–2A) or were on remission. 45.2% of dead...

... characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. Methods: This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients’ clinical and histological...

... and small cell lung carcinoma. New therapeutic agents for tumor stage mycosis fungoides (MF) have recently been developed, but their efficacy is limited. We herein retrospectively reported the use of MST-16/VP-16 combination therapy for tumor stage MF at multiple treatment centers and examined...

... is effective and safe in the treatment of advanced-stage CTCL and BPDCN. Cutaneous T-cell lymphoma Mycosis fungoides Sézary syndrome Peripheral T-cell lymphoma Blastic plasmacytoid dendritic cell neoplasia Treatment Gemcitabine Chemotherapy Progression-free survival Time to next treatment...

...Christiane Querfeld; Julia J. Scarisbrick; Chalid Assaf; Emmanuella Guenova; Martine Bagot; Pablo Luis Ortiz-Romero; Pietro Quaglino; Erminio Bonizzoni; Emmilia Hodak Background: Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Patients can be treated using chlormethine...

...Raed Alhusayen; Trang Tuyet Vu; Nouf Almuhanna; Iris Wohlmuth-Wieser; Jori Hardin; John-Douglas Matthew Hughes; Justin Chia; Leslie Street; Neil Hartley Shear; Scott Richard Walsh; Robert Gniadecki Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous...

...Maria Gluud; Simon Fredholm; Edda Blümel; Andreas Willerslev-Olsen; Terkild Brink Buus; Claudia Nastasi; Thorbjørn Krejsgaard; Charlotte Menné Bonefeld; Anders Woetmann; Lars Iversen; Thomas Litman; Carsten Geisler; Niels Ødum; Lise M. Lindahl Background: Mycosis fungoides (MF), the most common...

...>C and –1195A>G) polymorphisms and the risk of developing mycosis fungoides (MF). Methods: This was a hospital-based, case-control study of 70 MF patients and 100 MF-free controls. We genotyped COX-2 –1195A>G, –765G>C, and –8473T>C polymorphisms by using the PCR-restriction fragment...

...-gated potassium channel Kv1.3 (KCNA3) is expressed by effector memory T cells (T EM ) and plays an important role in their activation and proliferation. Mycosis fungoides (MF), the most common subtype of cutaneous T-cell lymphoma (CTCL), was recently proposed to be a malignancy of skin-resident T EM...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Dermoscopy Lymphoma Mycosis fungoides Lymphoproliferative disorders Clinical diagnosis of cutaneous...

...Mariah Giberson; Ahmed Mourad; Robert Gniadecki Background: Folliculotropic mycosis fungoides (FMF) is a distinct subtype of mycosis fungoides (MF) with unique clinicopathological features. The medical literature suggests that FMF has a more aggressive course and worse survival than classic MF...

...Esra Adışen; Volkan Tektaş; Funda Erduran; Özlem Erdem; Mehmet Ali Gürer Background: Phototherapy has been the mainstay of therapies for early mycosis fungoides (MF). The beneficial role of ultraviolet (UV) light on MF is suggested by the observation that lesions occur on non-sun-exposed areas...

...Eve Lebas; Jorge E. Arrese; Arjen F. Nikkels Background: Mycosis fungoides (MF) is the most frequent type of primary cutaneous natural killer and T-cell lymphoma. MF-required immunosuppressive therapies and MF-related immunosuppressive characteristics render patients with MF more prone...

...Paolo Fava; Massimiliano Bergallo; Chiara Astrua; Matteo Brizio; Ilaria Galliano; Paola Montanari; Pier Angelo Tovo; Mauro Novelli; Paola Savoia; Pietro Quaglino; Maria Teresa Fierro Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most frequent cutaneous T-cell lymphomas (CTCL...

...Marco Di Mercurio; Paolo Gisondi; Chiara Colato; Donatella Schena; Giampiero Girolomoni Background: Annular lichenoid dermatitis of youth (ALDY) is an uncommon disease clinically reminiscent of morphea, annular erythema or mycosis fungoides. Objective: To describe the histological and clinical...

...: To investigate 11 primary cutaneous anaplastic large cell lymphomas (PCALCL), 47 lymphomatoid papuloses (LYP) and 14 cases of transformed mycosis fungoides with CD30 expression (MF-T) for Gal-3 expression. Methods: A Gal-3 score was applied using a photo-based morphometric evaluation program. Double staining...

... cases of mycosis fungoides (MF) and to determine vascular patterns in MF dermoscopically. Methods: 25 patients with MF and 20 healthy controls were included. The MF lesions were assessed dermoscopically. CD34 immunohistochemistry was performed to count dermal microvessel density (MVD). Results...

... stage (stages IIB-IV) and presence of a CD8+CD4- mycosis fungoides phenotype were associated with the development of vitiligo. After adjusting for disease stage, increased risk of vitiligo was associated with methotrexate and CD4 antibody therapies (although the total number of patients...

...Ricardo Fernández-de-Misa; Buenaventura Hernández Machín; Armando Aguirre-Jaime; Lina Inmaculada Pérez-Méndez; Yeray Peñate; José Suárez Hernández Background: Patch or plaque stages in mycosis fungoides (MF) have different prognoses. The recent staging system proposed for MF discriminates between...